Stockreport

AIM ImmunoTech Announces Closing of its Rights Offering [Yahoo! Finance]

AIM ImmunoTech Inc.  (AIM) 
PDF the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreati [Read more]